Novo Nordisk receives US FDA approval of REBINYN® (nonacog beta pegol; N9-GP)

Udgivet den 31-05-2017  |  kl. 20:53  |  

Bagsværd, Denmark, 31 May 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® for the treatment of adults and children with haemophilia B.

REBINYN® is the brand name for nonacog beta pegol; N9-GP. REBINYN® is indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding around the time of surgery in adults and children with haemophilia B. The efficacy and safety evaluation was based on 115 patients across the four paradigm clinical trials, and the approval follows the Blood Products Advisory Committee meeting held 4 April 2017.

We are excited about the approval of REBINYN® in the US, and we consider it an important expansion of the treatment options for patients with haemophilia B, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. We are confident that REBINYN® will become an important tool for physicians to help patients manage their bleeds.

Novo Nordisk expects to launch REBINYN® in the US in the first half of 2018.

About REBINYN®

REBINYN® (nonacog beta pegol; N9-GP) is an extended half-life factor IX molecule for replacement therapy in patients with haemophilia B. The review of REBINYN® was based on the paradigm programme, a phase 3 clinical programme enrolling children and adults with severe or moderately severe haemophilia B. In the programme, 115 previously treated patients had a total of more than 8,800 exposure days for up to 2.7 years of treatment with REBINYN®. On 24 March 2017, Novo Nordisk received the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), for nonacog beta pegol; N9-GP, indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescent (>12 years of age) and adult patients with haemophilia B.
    

Further information

Media:    
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 40 / 2017 


PR170531_Rebinyn_US_approval_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

11:36 Aktier/middag: Danske Bank brager op efter milliardudbytte - revanche til Novo og Zealand
11:01 Topdanmark: Topchef henter 5,4 mio. kr. på at sælge aktier efter udnyttelse af optioner
10:32 Danske Banks topchef: Mindre vigtigt om der kommer en eller to rentenedsættelser i år
10:21 Microsoft og Crowdstrike ramt af nedbrud: Aktierne falder i formarkedet
10:19 Pengeregn til Danske Bank-aktionærer - vil sende 27 milliarder tilbage
10:19 ECB's Simkus ser plads til to rentelettelser mere i år
09:59 Stort it-nedbrud rammer politi, lufthavne og medier verden over
09:28 Svensk entreprenør belønnes for stærkt andet kvartal
09:13 Aktier/åbning: Danske Bank belønnes for stærk bundlinje og udbytte - Mærsk sejler ned
09:10 Containerrateindeks sætter sig for anden uge i træk
08:55 Obligationer/åbning: Højere rente som ventet fra start
08:31 Danske Bank lover storstilet udlodning til aktionærerne efter stærkt andet kvartal
08:23 Aktier/tendens: Danske Bank i fokus efter volatil uge - C25 nede 4 pct. siden fredag
08:07 Pengeregn til Danske Bank-aktionærer - varsler udbytte på over 22 mia. kr.
07:59 Råvarer: Oliepriserne falder for anden uge i træk efter blandede økonomiske signaler
07:02 Obligationer/tendens: Højere rente i sigte fra start
06:58 Novo Nordisk får hævet kursmålet hos britisk børshus
06:47 Asien: Kursfaldene fortsætter ufortrødent
06:35 Noble vil afnoteres fra børsen i København
06:34 Novo Nordisk får hævet kursmålet hos britisk børshus